Do you want to publish a course? Click here

The effect of diabetes mellitus type II on pulmonary function

دراسة تأثير الداء السكري نمط II على وظائف الرئة

2409   2   116   0 ( 0 )
 Publication date 2017
  fields Medicine
and research's language is العربية
 Created by Shamra Editor




Ask ChatGPT about the research

Background: Diabetes mellitus is a leading public health problem with increasing incidence and long term complications. These complications are mainly a consequence of macro-vascular and microvascular damages of the target organs. The incidence of several pulmonary abnormalities during the course of Diabetes Mellitus because the presence of an extensive microvascular circulation and abundant connective tissue in the lungs , raises the possibility that lung tissue may be a target organ in diabetic patients. Objectives: This research is designed to study the impact of DM and both the duration of the disease and the glycemic control on pulmonary function tests. Methodology: This is a cross-sectional study carried out on 75 patients with type II diabetes mellitus patients at Tishreen University Hospital in the period between October 2015 and October 2016 .We compared with a control group consisted of 75 non diabetic healthy persons . Measurement of HbA1C , fasting plasma glucose (FPG) , and spirometry were made to all subjects and the following pulmonary function parameters were recorded: Forced Expiratory Volume in the first second (FEV1), Forced Vital Capacity (FVC), and Forced Expiratory Volume percent (FEV1/ FVC%) . Results were analyzed by calculating Mean ± SD, using X2 test , Karl Pearson correlation and ANOVA test. Results: The mean FEV1, FVC, FEV1/FVC% values were low in diabetics (p value <0.05) compared to healthy non-diabetics (control group). Also, uncontrolled diabetics show a greater decrease in these values than controlled diabetics. There was a greater decrease in these values in patients with long period of disease . Conclusion: The findings of the present study suggest that, the lung is a target organ for damage in DM and diabetics show a decrease in PFTs with a restrictive pattern lesion compared with non-diabetics . And this deterioration is exaggerated in uncontrolled diabetics and with the long duration of DM .

References used
World Health Organization. Report of WHO study group. WHO Technical Report Series1985; No 727
WILD S, ROGLIC G, GREEN A. Global prevalence of diabetes. Diabetes Care 2004;27:1047-1053.2
GUYTON AC, HALL JE. Textbook of Medical physiology. 11thEdition. Elsevier Inc, New Delhi.2006
rate research

Read More

The objectives of this study were to assess the changes in pulmonary function after surgical correction of deviated nasal septum for nasal obstruction. Methods: A total of 81 patients with DNS with the complaints of nasal obstruction underwent septop lasty were involved in this before-after prospective study. Demographic data, clinical and physical examination including anterior and posterior rhinoscopy was performed. Pre- and post-surgery (after 1 and 3 month) spirometry was done on these patients. FVC, FEV1, PEFR, FEF25-75% and the ratio of FEV1 to FVC were the parameters measured. And the results were analyzed using various statistical tools for difference in spirometry findings depending on age group, gender, smoking and duration of disease. Results: Postoperative all PFT values, except for FEV1/FVC% value, were significantly higher than the preoperative values. Postoperative FEV1/FVC% value was significantly lower than preoperative value. The improvement was more in younger age groups, and it was more in nasal obstruction of shorter duration. There was no significant difference in improvement among males and females or among smoker and non-smokers. Conclusion: These findings suggest that septoplasty has a positive effect on pulmonary functions improvement in patients with nasal obstruction due to deviated nasal septum. And this improvement may be affected by age and the duration of obstruction, but not related to gender or smoking.
Blood glucose control reduces the microvascular and macrovascular complications in patients with diabetes mellitus type II. According to the American Diabetes Association, less than a half of those with diabetes achieve optimal control of blood gluc ose and target values of HbA1c. Life style modifications is one of the preferences of diabetes management because the potential relationship between diet and diabetic control. So nutrition therapy which given by dietitian and generally lifestyle modifications are considered mainly integrated to traditional medication for disease. The study included 104 patients with diabetes type II (HbA1c 8% ± 1.07, BMI 26.45 ± 2.69, fasting blood glucose 148.25 ± 33.76) given diabetes self-management education program and divided into two groups. The first group was treated with glibenclamide only and the second was treated with a combination of glibenclamide and metformin. After three months monitoring, 103 patients Completed the study. Therapeutic efficacy was evaluated considering HbA1c ≤ 6.5% as a target value. The necessary statistical study to analyze the data and evaluate the statistical significance of the results was made. The results indicate that the treatment supported with life style modifications was more effective than traditional therapy and patient education at blood glucose control in patients with diabetes mellitus type II and improve their health.
The study included 184 patients with type 2 diabetes referred to the specialist clinic or admitted in the sections of Al-Assad University Hospital in Damascus during the years 2012-2013. The patients were divided into three groups: Group A: a group of patients with diabetes is not treated with Metformin, 72 patients (39,1%). Group B: a group of patients with diabetes is treated with Metformin for more than 18 months, 72 patients (39,1%). Group C: a group of patients with diabetes is treated with Metformin for less than 6 months, 40 patients (21,8%). This study showed that 43,5% of the patients have Vit B12 deficiency: 32,6% of patients with diabetes treated with Metformin compared with 10,9% non treated with Metformin. The patients who were treated with Metformin (112 patients) were divided by dose intake and then depending on the duration of treatment into two groups for each category and shown an inverse correlation between duration and dose of therapy with metformin and levels of Vit B12. We also found that despite the increased risk of Vit B12 deficiency in patients with diabetes treated with Metformin but this was not associated with the occurrence of symptoms such as megaloplastic anemia and neurological symptoms.
Many T2D use CAO as a laxative. We did not find sufficient research to explain CAO's potential effect on the levels of HbA1c in T2D patients. This study will study this effect. Rats (n=80) were divided into eight groups (n=10). Five groups (n=50) wer e injected with streptozotocin intravenously to induce T2D. One group was given CAO with empagliflozin, and the second was assigned CAO only daily. The third was assigned CAO every two days, with empagliflozin, which was given daily. A fourth was assigned CAO alone daily. Also, the fifth was given empagliflozin alone. In the healthy groups, one group was given CAO, and the other was given empagliflozin. Also, the last healthy group was not assigned any drug. CAO's result on HbA1c in healthy rats was noted to decrease when delivered alone for eight weeks. HbA1c of the diabetic groups showed no significant difference (P-value<0.05) when comparing the rats given CAO with empagliflozin, and the rats were given CAO only. There was also no noticeable effect among the groups of rats given CAO daily and every two days. This study explains that CAO does not lead to a significant difference in HbA1c levels in diabetic rats, even it did for healthy rats, and if given alone, CAO could affect HbA1c levels if given over a long period. Also, CAO has a noticeable impact on experimental rats that co-administered Empagliflozin on HbA1c levels, and that Empagliflozin effect is not significantly affected if taken with CAO.
Background: Diabetes mellitus type2 (T2DM) and thyroid dysfunction (TD) are the two most common endocrine disorders in clinical practice. The unrecognized TD may adversely affect the metabolic control and add more risk to an already predisposing s cenario for cardiovascular diseases. The objective of this study was to investigate the prevalence of TD in patients with type2 diabetes mellitus. Objective: To determine the prevalence and patterns of thyroid dysfunction in patients with type2 diabetes mellitus. Material and methods: Study included total 362 subjects (204 type2 diabetic patients and 158 healthy non diabetic subjects). Agroup of type2 diabetic patients and control group were evaluated for thyroid dysfunction by testing TSH and FT4 when TSH was abnormal. The correlation of prevalence of thyroid disorder with gender distribution, age distribution, duration of diabetes, BMI, treatment, fasting plasma glucose (FPG), serum triglyceride and serum cholesterol was then done in diabetic patients. The observations and interpretations were recorded and results obtained were statistically analyzed. Results: The prevalence of thyroid dysfunction among type2 diabetic patients was found to be 13,2%. In the control group, the prevalence of thyroid dysfunction was 6,3%. There was a significant difference between diabetics and control subjects p= 0,031.The most frequently TD in type2 diabetic patients was subclinical hypothyroidism (8,3%). Thyroid dysfunction was significantly correlated with gender (women > man), age < 60 years, FPG > 130mg/dl, TG > 150mg/dl and insulin treatment in type2 diabetic patients. Conclusion: Screening of thyroid dysfunction shoud be done in all Type2 diabetic patients.

suggested questions

comments
Fetching comments Fetching comments
Sign in to be able to follow your search criteria
mircosoft-partner

هل ترغب بارسال اشعارات عن اخر التحديثات في شمرا-اكاديميا